AVAH

EX-99.1

2 avah-ex99_1.htm

EX-99.1

EX-99.1

Exhibit 99.1

AVEANNA HEALTHCARE HOLDINGS ANNOUNCES SECOND

QUARTER FINANCIAL RESULTS AND REVISED 2026 GUIDANCE

• Second Quarter Revenue was $670.5 million, a 13.7% increase over the prior year period

• Second Quarter Net income was $40.3 million compared to $27.0 million for the prior year period

• Adjusted EBITDA for Q2 2026 was $95.4 million, an 8.0% increase over the prior year period

• Increased Full Year 2026 Revenue guidance to greater than $2.68 billion, updated from between $2.63 and $2.65 billion

o Increased Full Year 2026 Adjusted EBITDA guidance to greater than $365 million, updated from between $338 and $342 million

Atlanta, Georgia (August 13, 2026) – Aveanna Healthcare Holdings Inc. (NASDAQ: AVAH), a leading, diversified home care platform focused on providing care to medically complex, high-cost patient populations, today announced financial results for the three and six-month periods ended July 4, 2026.

Jeff Shaner, Chief Executive Officer, commented, “Our second quarter results demonstrate the momentum across Aveanna and our ability to consistently deliver sustained year-over-year growth. Revenue and Adjusted EBITDA increased 13.7% and 8.0%, respectively, compared to the prior-year period, reflecting our strong organic growth across all three business segments. Our results reinforce the strength of our operating model, the continued success of our Preferred Payor and Government Affairs strategies, and the dedication of our team to deliver exceptional care to patients and families. Given our performance in the first half of the year and confidence in our outlook, we are pleased to raise our 2026 revenue and Adjusted EBITDA guidance.”

Three-Month Periods Ended July 4, 2026 and June 28, 2025

Revenue was $670.5 million for the three-month period ended July 4, 2026, as compared to $589.6 million for the three-month period ended June 28, 2025, an increase of $80.9 million, or 13.7%. The overall increase in revenue was attributable to a $67.9 million increase in PDS segment revenue, an $8.9 million increase in HHH segment revenue, and a $4.1 million increase in MS segment revenue compared to the second quarter of 2025.

Gross margin was $218.5 million, or 32.6% of revenue, for the three-month period ended July 4, 2026, as compared to $210.8 million, or 35.8% of revenue, for the three-month period ended June 28, 2025, an increase of $7.7 million, or 3.7%.

Net income was $40.3 million or 6.0% of revenue, for the three-month period ended July 4, 2026, as compared to net income of $27.0 million, or 4.6% of revenue for the three-month period ended June 28, 2025. Net income per diluted share was $0.18 for the three-month period ended July 4, 2026, as compared to net income per diluted share of $0.13 for the three-month period ended June 28, 2025. Adjusted net income per diluted share was $0.22 for the three-month period ended July 4, 2026, as compared to adjusted net income per diluted share of $0.18 for the three-month period ended June 28, 2025. See "Non-GAAP Financial Measures - Adjusted net income and Adjusted net income per diluted share" below.

Adjusted EBITDA was $95.4 million, or 14.2% of revenue, for the three-month period ended July 4, 2026, as compared to $88.4 million, or 15.0% of revenue, for the three-month period ended June 28, 2025, an increase of $7.1 million or 8.0%. See "Non-GAAP Financial Measures - EBITDA and Adjusted EBITDA" below.

Six-Month Periods Ended July 4, 2026 and June 28, 2025

1

Revenue was $1,318.4 million for the six-month period ended July 4, 2026, as compared to $1,148.8 million for the six-month period ended June 28, 2025, an increase of $169.6 million, or 14.8%. The overall increase in revenue was attributable to a $143.6 million increase in PDS segment revenue, an $18.8 million increase in HHH segment revenue, and a $7.3 million increase in MS segment revenue compared to the first six months of 2025.

Gross margin was $424.0 million, or 32.2% of revenue, for the six-month period ended July 4, 2026, as compared to $394.4 million, or 34.3% of revenue, for the six-month period ended June 28, 2025, an increase of $29.6 million, or 7.5%.

Net income was $81.9 million or 6.2% of revenue for the six-month period ended July 4, 2026, as compared to net income of $32.2 million or 2.8% of revenue for the six-month period ended June 28, 2025. Net income per diluted share was $0.37 for the six-month period ended July 4, 2026, as compared to net income per diluted share of $0.16 for the six-month period ended June 28, 2025. Adjusted net income per diluted share was $0.40 for the six-month period ended July 4, 2026, as compared to adjusted net income per diluted share of $0.28 for the six-month period ended June 28, 2025. See "Non-GAAP Financial Measures - Adjusted net income and Adjusted net income per diluted share" below.

Adjusted EBITDA was $179.8 million, or 13.6% of revenue, for the six-month period ended July 4, 2

EX-99.1

2 avah-ex99_1.htm

EX-99.1

EX-99.1

Exhibit 99.1

AVEANNA HEALTHCARE HOLDINGS ANNOUNCES FIRST

QUARTER FINANCIAL RESULTS AND REVISED 2026 GUIDANCE

• First Quarter Revenue was $647.9 million, a 15.9% increase over the prior year period

• First Quarter Net income was $41.7 million compared to $5.2 million for the prior year period

• Adjusted EBITDA for Q1 2026 was $84.4 million, a 25.2% increase over the prior year period

• Increased Full Year 2026 Revenue guidance to between $2.56 and $2.58 billion, updated from between $2.54 and $2.56 billion

o Increased Full Year 2026 Adjusted EBITDA guidance to between $328 and $332 million, updated from between $318 and $322 million

Atlanta, Georgia (May 14, 2026) – Aveanna Healthcare Holdings Inc. (NASDAQ: AVAH), a leading, diversified home care platform focused on providing care to medically complex, high-cost patient populations, today announced financial results for the three-month period ended April 4, 2026.

Jeff Shaner, Chief Executive Officer, commented, “Q1 reflects the strength and resiliency of our business model with an impressive start to 2026. Our first quarter results saw revenue and adjusted EBITDA increase 15.9% and 25.2%, respectively, when compared to the prior year period, and our guidance has been revised to reflect the positive momentum we see in 2026. Our Preferred Payor and Government Affairs strategies underpin the continued growth across all of our business segments. Most importantly, our clinical teams continue to deliver on our mission, bringing high quality care to our patients in the comfort of their homes. While we finalize the regulatory approval process on the Family First Homecare transaction, our focus remains on delivering strong organic growth across Aveanna’s national footprint. Finally, thank you to our Aveanna team for your hard work, dedication, and commitment to exceptional care. You are the true heart of our company."

Three-Month Period Ended April 4, 2026 and March 29, 2025

Revenue was $647.9 million for the three-month period ended April 4, 2026, as compared to $559.2 million for the three-month period ended March 29, 2025, an increase of $88.7 million, or 15.9%. The overall increase in revenue was attributable to a $75.7 million increase in PDS segment revenue, a $9.9 million increase in HHH segment revenue, and a $3.2 million increase in MS segment revenue compared to the first three months of 2025.

Gross margin was $205.4 million, or 31.7% of revenue, for the three-month period ended April 4, 2026, as compared to $183.6 million, or 32.8% of revenue, for the three-month period ended March 29, 2025, an increase of $21.9 million, or 11.9%.

Net income was $41.7 million for the three-month period ended April 4, 2026, as compared to net income of $5.2 million for the three-month period ended March 29, 2025. Net income per diluted share was $0.19 for the three-month period ended April 4, 2026, as compared to net income per diluted share of $0.03 for the three-month period ended March 29, 2025. Adjusted net income per diluted share was $0.18 for the three-month period ended April 4, 2026, as compared to adjusted net income per diluted share of $0.10 for the three-month period ended March 29, 2025. See "Non-GAAP Financial Measures - Adjusted net income and Adjusted net income per diluted share" below.

Adjusted EBITDA was $84.4 million, or 13.0% of revenue, for the three-month period ended April 4, 2026, as compared to $67.4 million, or 12.0% of revenue, for the three-month period ended March 29, 2025, an increase of $17.0 million or 25.2%. See "Non-GAAP Financial Measures - EBITDA and Adjusted EBITDA" below.

1

Liquidity, Cash Flow, and Debt

• As of April 4, 2026, we had cash of $189.3 million and incremental borrowing capacity of $110.0 million under our securitization facility. Our revolver was undrawn, with approximately $225.5 million of borrowing capacity and approximately $24.5 million of outstanding letters of credit. The pending acquisition, which is being funded with a combination of cash on hand and borrowings under our securitization facility, is expected to reduce our liquidity upon the closing of the transaction.

• 2026 net cash provided by operating activities was $4.3 million. Free cash flow was $(3.8) million for the three-month ended April 4, 2026. See “Non-GAAP Financial Measures - Free cash flow” below.

• As of April 4, 2026 we had total indebtedness of $1,483.4 million. Our interest rate exposure under our credit facilities is currently hedged with the following instruments:

o $520.0 million notional amount of interest rate swaps that convert variable rate debt to a fixed rate, and

o $880.0 million notional amount of interest rate caps that cap our exposure to SOFR at 2.96%.

Matt Buckhalter, Chief Financial Officer, commented “We are pleased with our strong start to 2026. Our team continued to execute at a high level across all three divisions. For the first quarter, we delivered reven

EX-99.1

2 avah-ex99_1.htm

EX-99.1

EX-99.1

Exhibit 99.1

AVEANNA HEALTHCARE HOLDINGS ANNOUNCES FOURTH

QUARTER AND FULL YEAR 2025 FINANCIAL RESULTS

• Fourth Quarter Revenue was $662.5 million, a 27.4% increase over the prior year period

• Fourth Quarter Net income was $178.8 million compared to $29.2 million for the prior year period

• Adjusted EBITDA for Q4 2025 was $85.0 million, a 54.0% increase over the prior year period

• Maintained Full Year 2026 Revenue guidance of between $2.54 and $2.56 billion

o Maintained Full Year 2026 Adjusted EBITDA guidance of between $318 and $322 million

• Announced agreement to acquire Family First Homecare subsequent to the Fourth Quarter

Atlanta, Georgia (March 19, 2026) – Aveanna Healthcare Holdings Inc. (NASDAQ: AVAH), a leading, diversified home care platform focused on providing care to medically complex, high-cost patient populations, today announced financial results for the three-month period and fiscal year ended January 3, 2026.

Jeff Shaner, Chief Executive Officer, commented, “The strength and momentum of all three operating divisions can be seen in our fourth quarter results as we complete the third year of our Strategic Transformation. Fourth quarter results are headlined by revenue and adjusted EBITDA growth of 27.4% and 54.0%, respectively, when compared to the prior year period. With the integration of Thrive Skilled Pediatric Care completed, we are well-positioned for further acquisition activity, including the recently announced Family First Homecare transaction. Our confirmed guidance underscores the strength of our core business model as we continue to provide high quality and cost-effective care to our patients in their preferred care setting – the home. These results reflect the extraordinary efforts and the determination of our entire team at Aveanna, who deliver on our mission of exceptional care every day.”

Three-Month Periods Ended January 3, 2026 (14 weeks) and December 28, 2024 (13 weeks)

Revenue was $662.5 million for the three-month period ended January 3, 2026, as compared to $519.9 million for the three-month period ended December 28, 2024, an increase of $142.6 million, or 27.4%. The overall increase in revenue was attributable to a $118.5 million increase in PDS segment revenue, a $14.9 million increase in HHH segment revenue, and a $9.2 million increase in MS segment revenue compared to the fourth quarter of 2024.

Gross margin was $213.3 million, or 32.2% of revenue, for the three-month period ended January 3, 2026, as compared to $171.7 million, or 33.0% of revenue, for the three-month period ended December 28, 2024, an increase of $41.6 million, or 24.2%.

Net income was $178.8 million for the three-month period ended January 3, 2026, as compared to net income of $29.2 million for the three-month period ended December 28, 2024. Net income per diluted share was $0.80 for the three-month period ended January 3, 2026, as compared to net income per diluted share of $0.14 for the three-month period ended December 28, 2024. Adjusted net income per diluted share was $0.17 for the three-month period ended January 3, 2026, as compared to adjusted net income per diluted share of $0.05 for the three-month period ended December 28, 2024. See "Non-GAAP Financial Measures - Adjusted net income and Adjusted net income per diluted share" below.

Adjusted EBITDA was $85.0 million, or 12.8% of revenue, for the three-month period ended January 3, 2026, as compared to $55.2 million, or 10.6% of revenue, for the three-month period ended December 28, 2024, an increase of $29.8 million or 54.0%. See "Non-GAAP Financial Measures - EBITDA and Adjusted EBITDA" below.

Year Ended January 3, 2026 and December 28, 2024

1

Revenue was $2,433.2 million for the fiscal year ended January 3, 2026, as compared to $2,024.5 million for the fiscal year ended December 28, 2024, an increase of $408.7 million, or 20.2%. The overall increase in revenue was attributable to a $366.5 million increase in PDS segment revenue, a $30.8 million increase in HHH segment revenue, and a $11.4 million increase in MS segment revenue compared to the fiscal year 2024.

Gross margin was $810.5 million, or 33.3% of revenue, for the fiscal year ended January 3, 2026, as compared to $635.5 million, or 31.4% of revenue, for the fiscal year ended December 28, 2024, an increase of $174.9 million, or 27.5%.

Net income was $225.0 million for the fiscal year ended January 3, 2026, as compared to net loss of $10.9 million for the fiscal year ended December 28, 2024. Net income per diluted share was $1.05 for the fiscal year ended January 3, 2026, as compared to net loss per diluted share of $(0.06) for the fiscal year ended December 28, 2024. Adjusted net income per diluted share was $0.60 for the fiscal year ended January 3, 2026, as compared to adjusted net income per diluted share of $0.06 for the fiscal year ended December 28, 2024. See "Non-GAAP Financial Measures - Adjusted net incom